Hyderabad-based pharmaceutical major Aurobindo Pharma has indicated that its biosimilars segment is expected to become a significant growth driver for the company, with management identifying 2029 as a key milestone year for the business.
During the company’s recent quarterly earnings interaction, senior leadership said the organization is transitioning from the development stage into full-scale commercialization of biosimilar products across global markets. The company has already built a pipeline of multiple biologic and biosimilar therapies and plans to expand regulatory filings in major regulated markets including the United States and Europe.
Management believes these approvals, along with ongoing launches, will start contributing meaningfully to revenue toward the end of the decade. The company is aiming to establish broad coverage in the European region while also exploring growth opportunities in Latin America and other regulated geographies.
Expansion Across Global Markets
Aurobindo Pharma has been strengthening its presence in international markets through its biologics division. Some of its approved oncology biosimilar therapies are already available in select international markets, and additional products are under development and regulatory review. The company is also working with regional partners in certain countries to accelerate commercialization and improve market access.
In addition, regulatory inspections in countries such as Brazil are expected to open new pathways for approvals and product launches in the near future.
Building a Long-Term Biosimilars Portfolio
The company plans to build a diversified biosimilars portfolio over the next several years, with a long-term target of introducing around 15 products. Aurobindo believes the global regulatory environment is gradually becoming more supportive for biosimilars, which could help faster adoption and market expansion.
Industry initiatives in India supporting biologics manufacturing and research are also seen as positive developments. However, building domestic capabilities in clinical research and maintaining strict quality standards will be essential for global competitiveness.
Manufacturing and Penicillin Business Update
Alongside biologics, Aurobindo is also expanding utilization of its penicillin manufacturing facility in Andhra Pradesh. The company expects higher production levels over the next year and is working on cost-optimization measures to remain competitive with global suppliers. Government measures affecting imports of certain antibiotic intermediates are also expected to support domestic production.
Financial Performance
For the latest reported quarter, Aurobindo Pharma recorded steady growth in revenue along with improved margins. The European business showed strong expansion, while the US market posted moderate growth. The company continues to invest in research and development to support future product launches.
Management remains confident of achieving substantial European revenues in the current financial year and expects continued growth in the injectables segment in the United States.
Outlook
Aurobindo Pharma’s leadership believes that biosimilars will play a central role in the company’s long-term strategy. As commercialization expands and regulatory approvals increase, the business could become a major contributor to overall revenue by the end of the decade. The company is positioning itself to benefit from rising global demand for affordable biologic medicines, especially in oncology and specialty therapeutic areas.